195 related articles for article (PubMed ID: 22295228)
1. Obesity is an independent predictor of poor survival in metastatic breast cancer: retrospective analysis of a patient cohort whose treatment included high-dose chemotherapy and autologous stem cell support.
von Drygalski A; Tran TB; Messer K; Pu M; Corringham S; Nelson C; Ball ED
Int J Breast Cancer; 2011; 2011():523276. PubMed ID: 22295228
[TBL] [Abstract][Full Text] [Related]
2. Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.
Schneeweiss A; Hensel M; Sinn P; Khbeis T; Haas R; Bastert G; Ho AD
Ann Oncol; 2002 May; 13(5):679-88. PubMed ID: 12075735
[TBL] [Abstract][Full Text] [Related]
3. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysis of sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program.
Elias AD; Ibrahim J; Richardson P; Avigan D; Joyce R; Reich E; McCauley M; Wheeler C; Frei E
Biol Blood Marrow Transplant; 2002; 8(4):198-205. PubMed ID: 12017145
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer.
Hamilton BK; Rybicki L; Abounader D; Andresen S; Kalaycio M; Sobecks R; Pohlman B; Hanna R; Dean R; Liu H; Hill B; Bolwell B; Copelan E
Hematol Oncol Stem Cell Ther; 2015 Sep; 8(3):115-24. PubMed ID: 26183670
[TBL] [Abstract][Full Text] [Related]
5. Stem cell dose and tumorbiologic parameters as prognostic markers for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous blood stem cell support.
Hensel M; Schneeweiss A; Sinn HP; Egerer G; Kornacker M; Solomayer E; Haas R; Bastert G; Ho AD
Stem Cells; 2002; 20(1):32-40. PubMed ID: 11796920
[TBL] [Abstract][Full Text] [Related]
6. Impact of body mass index on overall survival in patients with metastatic breast cancer.
Saleh K; Carton M; Dieras V; Heudel PE; Brain E; D'Hondt V; Mailliez A; Patsouris A; Mouret-Reynier MA; Goncalves A; Ferrero JM; Petit T; Emile G; Uwer L; Debled M; Dalenc F; Jouannaud C; Ladoire S; Leheurteur M; Cottu P; Veron L; Savignoni A; Courtinard C; Robain M; Delaloge S; Deluche E
Breast; 2021 Feb; 55():16-24. PubMed ID: 33307392
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16.
Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI
J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439
[TBL] [Abstract][Full Text] [Related]
8. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
Farquhar C; Marjoribanks J; Basser R; Hetrick S; Lethaby A
Cochrane Database Syst Rev; 2005 Jul; 2005(3):CD003142. PubMed ID: 16034887
[TBL] [Abstract][Full Text] [Related]
9. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer.
Farquhar C; Basser R; Hetrick S; Lethaby A; Marjoribanks J
Cochrane Database Syst Rev; 2003; (1):CD003142. PubMed ID: 12535458
[TBL] [Abstract][Full Text] [Related]
10. Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.
Martel S; Poletto E; Ferreira AR; Lambertini M; Sottotetti F; Bertolini I; Montemurro F; Bernardo A; Risi E; Zanardi E; Ziliani S; Mura S; Dellepiane C; Del Mastro L; Minisini AM; Puglisi F
Breast; 2018 Feb; 37():142-147. PubMed ID: 29161652
[TBL] [Abstract][Full Text] [Related]
11. Role of High-Dose Adjuvant Chemotherapy Followed by Autologous Stem Cell Transplantation in Locally Advanced Triple-Negative Breast Cancer: A Retrospective Chart Review.
Al-Share B; Assad H; Abrams J; Deol A; Alavi A; Modi D; Kin A; Ratanatharathorn V; Uberti J; Ayash L
J Oncol; 2022; 2022():3472324. PubMed ID: 36213836
[TBL] [Abstract][Full Text] [Related]
12. Complete response after high-dose chemotherapy and autologous hemopoietic stem cell transplatation in metastatic breast cancer results in survival benefit.
Kurian S; Qazilbash M; Fay J; Wolff S; Herzig R; Hobbs G; Bunner P; Weisenborn R; Aya-Ay M; Lynch J; Ericson S
Breast J; 2006; 12(6):531-5. PubMed ID: 17238982
[TBL] [Abstract][Full Text] [Related]
13. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant.
Nieto Y; Shpall EJ; McNiece IK; Nawaz S; Beaudet J; Rosinski S; Pellom J; Slat-Vasquez V; McSweeney PA; Bearman SI; Murphy J; Jones RB
Clin Cancer Res; 2004 Aug; 10(15):5076-86. PubMed ID: 15297410
[TBL] [Abstract][Full Text] [Related]
14. Response-adapted treatment with upfront high-dose chemotherapy followed by autologous stem-cell transplantation rescue or consolidation phase high-dose methotrexate for primary central nervous system lymphoma: a long-term mono-center study.
Nakasu Y; Mitsuya K; Hayashi N; Okamura I; Mori K; Enami T; Tatara R; Nakasu S; Ikeda T
Springerplus; 2016; 5():307. PubMed ID: 27066340
[TBL] [Abstract][Full Text] [Related]
15. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
Stewart DA; Guo D; Glück S; Morris D; Chaudhry A; deMetz C; Klassen J; Brown CB; Russell JA
Bone Marrow Transplant; 2000 Aug; 26(4):383-8. PubMed ID: 10982284
[TBL] [Abstract][Full Text] [Related]
16. High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer.
Farquhar C; Marjoribanks J; Lethaby A; Azhar M
Cochrane Database Syst Rev; 2016 May; 2016(5):CD003139. PubMed ID: 27200512
[TBL] [Abstract][Full Text] [Related]
17. Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection.
Montemurro F; Rondón G; Munsell M; Smith TL; Donato ML; Gajewski JL; Rahman ZU; Buzdar AU; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2003 May; 9(5):330-40. PubMed ID: 12766883
[TBL] [Abstract][Full Text] [Related]
18. High dose chemotherapy with thiotepa, mitoxantrone and carboplatin (TMJ) followed by autologous stem cell support in 100 consecutive lymphoma patients in a single centre: analysis of efficacy, toxicity and prognostic factors.
Waheed F; Kancherla R; Seiter K; Liu D; Qureshi Z; Hoang A; Ahmed T
Leuk Lymphoma; 2004 Nov; 45(11):2253-9. PubMed ID: 15512814
[TBL] [Abstract][Full Text] [Related]
19. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
Klar N; Rosenzweig M; Diergaarde B; Brufsky A
Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
[TBL] [Abstract][Full Text] [Related]
20. A Multicenter Study of the Impact of Body Mass Index (BMI) on the incidence of Pathologic Complete Response (pCR) Among Saudi Patients with locally advanced Breast cancer (LABC) post Neoadjuvant Chemotherapy (NAC).
Al-Saleh K; Abd El-Aziz N; Ali A; Abo Zeed W; Salah T; Elsamany S; Rasmy A; El Farargy O; Husain S; Al-Rikabi A; Alsaeed E; Aldiab A; Abd El-Warith A
Gulf J Oncolog; 2019 May; 1(30):33-42. PubMed ID: 31242980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
